# Emperra GmbH E-Health Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emperra-gmbh-e-health-technologies

- Industry: Healthcare IT
- Headquarters: Potsdam, Germany
- Website: www.emperra.com
- Total disclosed funding: $3.1M
- Latest round: Series B (Dec 12, 2015)
- Investors on record: 3

## About

Emperra GmbH develops advanced diabetes management solutions that enhance patient autonomy through innovative technology, primarily its flagship ESYSTA system, designed for seamless insulin and blood glucose monitoring.Founded in 2008 in Potsdam, Germany, Emperra GmbH specializes in diabetes management technology. Med Schildt is the CEO and founder, bringing prior entrepreneurial experience to the company. Emperra has raised USD 3.1 mn through two funding rounds, with the latest Series B round completed on December 12, 2015, led by InvestitionsBank des Landes Brandenburg, Peppermint VenturePartners, and Robert Bosch Venture Capital, achieving a total funding of USD 3.1 mn and a current valuation of USD 10.46 mn.Emperra® GmbH specializes in innovative diabetes management solutions, with its flagship product being the ESYSTA product system. Launched to alleviate the burdens of manual diabetes diary management, ESYSTA automates the storage and recording of insulin units and blood glucose readings. This system enhances patient autonomy by providing seamless data management that allows users to access their diabetes information at any time. The primary end users of ESYSTA include diabetes patients and healthcare professionals, such as diabetologists, who utilize the data for more informed treatment decisions. The product is particularly aimed at the European market, with a strong presence in Germany, where it supports a diverse range of clients from individual patients to healthcare institutions.Emperra® GmbH generates revenue through a subscription-based model for its ESYSTA product system, enabling users and healthcare professionals to access advanced diabetes management tools. The company’s revenue model involves partnerships with medical institutions and healthcare providers, allowing for broader distribution and the use of its technology. Transactions typically occur directly between Emperra and its clients, encompassing both healthcare providers and individual consumers who purchase or subscribe to the ESYSTA system. The pricing structure aligns with the advanced technological features and the comprehensive support provided, ensuring effective utilization of the system in managing diabetes.Emperra plans to leverage its recent Series B funding of USD 3.1 mn, raised in December 2015, to support the development of new products and enhance its market reach. Specific strategies include targeting expansion into new markets across Europe, aiming to launch updated features of the ESYSTA system within the next year. The funding will facilitate the design and deployment of additional diabetes management solutions, enhancing both product offerings and access to patients in underserved regions.

## Funding rounds

- Series B, Dec 12, 2015, $3.1M — Peppermint VenturePartners, Robert Bosch Venture Capital, InvestitionsBank des Landes Brandenburg

## Investors

- Peppermint VenturePartners (https://capitalatlas.ai/funds/peppermint-venturepartners) — Series B
- Robert Bosch Venture Capital (https://capitalatlas.ai/funds/robert-bosch-venture-capital) — Series B
- InvestitionsBank des Landes Brandenburg — Series B